This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
by Zacks Equity Research
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
PBYINegative Net Change DERMNegative Net Change ARGXPositive Net Change TRDAPositive Net Change
biotechs
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
BMYPositive Net Change LLYNegative Net Change BGNEPositive Net Change ALLOPositive Net Change TNGXPositive Net Change
biotechnology biotechs
bluebird (BLUE) Stock Down on Raising Additional Capital
by Zacks Equity Research
bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.
VRTXNegative Net Change CRSPPositive Net Change TRDAPositive Net Change
biotechnology biotechs
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
PFEPositive Net Change NVONegative Net Change MRKPositive Net Change GLPGPositive Net Change
biotechs medical pharmaceuticals vaccines
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
by Zacks Equity Research
The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.
PBYINegative Net Change DERMNegative Net Change AVXLPositive Net Change TRDAPositive Net Change
biotechs
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
GILDPositive Net Change CGENPositive Net Change RCUSPositive Net Change ACLXPositive Net Change
biotechnology biotechs pharmaceuticals
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
by Kinjel Shah
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
NVONegative Net Change DERMNegative Net Change FUSNPositive Net Change LYRANegative Net Change
biotechs pharmaceuticals
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
by Zacks Equity Research
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
AGENPositive Net Change PBYINegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
by Zacks Equity Research
Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.
PBYINegative Net Change DERMNegative Net Change TRDAPositive Net Change IVVDPositive Net Change
biotechs
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
by Zacks Equity Research
The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.
PBYINegative Net Change DERMNegative Net Change ARQTPositive Net Change TRDAPositive Net Change
biotechs
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
by Zacks Equity Research
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
DVAXPositive Net Change MIRMPositive Net Change TVTXPositive Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
by Zacks Equity Research
The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
PFEPositive Net Change NVONegative Net Change MRKPositive Net Change PBYINegative Net Change
biotechs pharmaceuticals
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
by Zacks Equity Research
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
NVONegative Net Change MRKPositive Net Change GLPGPositive Net Change
biotechs medical pharmaceuticals vaccines
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
BMYPositive Net Change DVAXPositive Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
by Zacks Equity Research
Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
VRTXNegative Net Change EDITPositive Net Change CRSPPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
by Zacks Equity Research
Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.
BIIBPositive Net Change PTCTNegative Net Change PBYINegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
DVAXPositive Net Change ABBVNegative Net Change CRSPPositive Net Change
biotechnology biotechs pharmaceuticals
5 Big Drug Stocks That May Continue to Outperform in 2024
by Kinjel Shah
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
REGNPositive Net Change GSKPositive Net Change NVONegative Net Change LLYNegative Net Change VRTXNegative Net Change
biotechs pharmaceuticals
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change TRDAPositive Net Change
biotechnology biotechs
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
MRKPositive Net Change MRNAPositive Net Change GLPGPositive Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
MRKPositive Net Change MRNAPositive Net Change GLPGPositive Net Change
biotechs medical vaccines
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
by Zacks Equity Research
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
DVAXPositive Net Change MRKPositive Net Change NXTCNegative Net Change TRDAPositive Net Change
biotechnology biotechs
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
by Zacks Equity Research
Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.
AGENPositive Net Change PBYINegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA
by Zacks Equity Research
The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.
PBYINegative Net Change DERMNegative Net Change APLSNegative Net Change TRDAPositive Net Change
biotechs
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
by Zacks Equity Research
bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.
BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change
biotechs